Perceptive Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Perceptive Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,258,903	Closed	-$209M	–	112
2026 Q1	$209M	Buy	5,258,903 +2,341,269	+80%	+$59.9M	4.08%	5
2025 Q4	$73M	Sell	2,917,634 -183,268	-6%	-$4.64M	1.3%	25
2025 Q3	$75.2M	Buy	3,100,902 +1,953,967	+170%	+$34.7M	2.17%	15
2025 Q2	$15.1M	Sell	1,146,935 -1,893,460	-62%	-$24M	0.56%	44
2025 Q1	$43.7M	Sell	3,040,395 -3,308,825	-52%	-$54.1M	1.54%	16
2024 Q4	$106M	Buy	6,349,220 +66,930	+1%	+$1.11M	2.93%	9
2024 Q3	$100M	Buy	6,282,290 +2,348,983	+60%	+$28.8M	2.13%	12
2024 Q2	$35.5M	Buy	3,933,307 +850,000	+28%	+$8.06M	0.86%	33
2024 Q1	$34.8M	Buy	+3,083,307	New	+$29.2M	0.61%	51

Perceptive Advisors's CNTA Position: Q2 2026 in Review

Perceptive Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 5,258,903 shares — an estimated $209M sold.

Perceptive Advisors first reported a position in CNTA in Q1 2024 and held it in 9 quarters. The position peaked at $209M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Perceptive Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Perceptive Advisors sold 5,258,903 Centessa Pharmaceuticals shares in Q2 2026, an estimated $209M.
Perceptive Advisors first reported a position in Centessa Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Perceptive Advisors's Centessa Pharmaceuticals position peaked at $209M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.